Royalty PharmaRPRX
About: Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Employees: 89
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
1,323% more call options, than puts
Call options by funds: $20.8M | Put options by funds: $1.47M
32% more repeat investments, than reductions
Existing positions increased: 157 | Existing positions reduced: 119
29% more funds holding in top 10
Funds holding in top 10: 7 [Q2] → 9 (+2) [Q3]
28% more first-time investments, than exits
New positions opened: 59 | Existing positions closed: 46
3% more funds holding
Funds holding: 374 [Q2] → 387 (+13) [Q3]
8% less capital invested
Capital invested by funds: $9.5B [Q2] → $8.7B (-$795M) [Q3]
11.06% less ownership
Funds ownership: 79.68% [Q2] → 68.62% (-11.06%) [Q3]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Citigroup Andrew Baum 25% 1-year accuracy 1 / 4 met price target | 61%upside $40 | Buy Maintained | 25 Oct 2024 |
Financial journalist opinion
Based on 4 articles about RPRX published over the past 30 days
